Get the Stockscreener App
1.47
3.52%
0.05
After Hours:
1.43
-0.04
-2.72%
Aprea Therapeutics Inc stock is traded at $1.47, with a volume of 91,756.
It is up +3.52% in the last 24 hours and down -4.79% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$1.42
Open:
$1.41
24h Volume:
91,756
Relative Volume:
1.90
Market Cap:
$8.56M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.3684
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
-1.01%
1M Performance:
-4.79%
6M Performance:
-5.16%
1Y Performance:
-43.46%
1-Day Range:
$1.3999
$1.52
1-Week Range:
$1.395
$1.54
52-Week Range:
$1.37
$5.01
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.47 | 8.27M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Is Aprea Therapeutics Inc. stock poised for growthRecession Risk & Weekly High Potential Alerts - newser.com
Sentiment analysis tools applied to Aprea Therapeutics Inc.Market Activity Summary & Fast Exit/Entry Strategy Plans - newser.com
Developing predictive dashboards with Aprea Therapeutics Inc. dataInsider Selling & AI Powered Market Trend Analysis - newser.com
How to recover losses in Aprea Therapeutics Inc. stock2025 Technical Overview & Technical Buy Zone Confirmation - newser.com
Using economic indicators to assess Aprea Therapeutics Inc. potential2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
Should you wait for a breakout in Aprea Therapeutics Inc.July 2025 Selloffs & Smart Investment Allocation Insights - newser.com
Aprea Therapeutics (NASDAQ:APRE) Trading Down 3% – Here’s What Happened - Defense World
Historical volatility pattern of Aprea Therapeutics Inc. visualizedPortfolio Growth Summary & Daily Growth Stock Tips - newser.com
Can Aprea Therapeutics Inc. rally from current levelsWeekly Trend Report & Long-Term Growth Stock Strategies - newser.com
How sentiment analysis helps forecast Aprea Therapeutics Inc.Market Rally & Free Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-03 04:24:53 - newser.com
How to integrate Aprea Therapeutics Inc. into portfolio analysis toolsJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
Reversal indicators forming on Aprea Therapeutics Inc. stockJobs Report & Verified Chart Pattern Signals - newser.com
What analysts say about Aprea Therapeutics Inc stockPrice Support Zones & Low Cost Trading Plans - earlytimes.in
Published on: 2025-09-30 01:07:35 - newser.com
Published on: 2025-09-29 04:10:00 - newser.com
What drives Aprea Therapeutics Inc stock priceTrade Execution Strategies & Big Returns Small Capital - earlytimes.in
Is Aprea Therapeutics Inc a good long term investmentMACD Trading Signals & Rapid Capital Trading Tips - Early Times
Published on: 2025-09-27 17:04:35 - newser.com
Live market analysis of Aprea Therapeutics Inc.2025 Sector Review & Stock Portfolio Risk Control - newser.com
Using portfolio simulators with Aprea Therapeutics Inc. includedJuly 2025 Trends & Weekly Market Pulse Alerts - newser.com
Aug Gainers: Will Inhibrx Biosciences Inc stock recover after earningsJuly 2025 Closing Moves & Free Weekly Watchlist of Top Performers - خودرو بانک
Reviewing Aprea Therapeutics (NASDAQ:APRE) and Ventyx Biosciences (NASDAQ:VTYX) - Defense World
Understanding Aprea Therapeutics Inc.’s price movement2025 Major Catalysts & Real-Time Price Movement Reports - newser.com
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aprea Therapeutics Inc Stock (APRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Duey Marc | Director |
Oct 18 '24 |
Sale |
4.58 |
6,462 |
29,583 |
233,651 |
| Gilad Oren | President/CEO |
Oct 23 '24 |
Buy |
3.92 |
500 |
1,958 |
333,395 |
| Duey Marc | Director |
Oct 16 '24 |
Buy |
4.39 |
30,000 |
131,700 |
240,113 |
| Gilad Oren | President/CEO |
Oct 15 '24 |
Buy |
2.90 |
250 |
725 |
332,895 |
| Duey Marc | Director |
Oct 14 '24 |
Buy |
2.58 |
190 |
490 |
210,113 |
| Gilad Oren | President/CEO |
Oct 14 '24 |
Buy |
2.59 |
1,000 |
2,590 |
332,645 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):